Placebo News and Research

RSS

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Promising vaccine may provide new treatment option for patients with HER2-positive cancers

Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers who had not previously been treated with a HER2-targeted therapeutic, according to data from a phase I clinical trial presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.

30 Sep 2018

Early Parkinson’s disease patients wait too long before seeking medical attention

The time between diagnosis and the institution of symptomatic treatment is critical in the effort to find a cure for Parkinson's Disease.

29 Sep 2018

Non-small cell lung cancer patients survive longer when treated with durvalumab

Non-small cell lung cancer patients survive longer when their treatment includes durvalumab following platinum-based chemoradiotherapy, according to research led by Moffitt Cancer Center.

27 Sep 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Novel therapy technique double rate of upper limb recovery in stroke patients

A novel therapy technique invented by researchers at The University of Texas at Dallas has been shown in a pilot study to double the rate of upper limb recovery in stroke patients, a leap forward in treating the nearly 800,000 Americans who suffer strokes each year.

27 Sep 2018

Mesoblast’s MPC therapy for children featured at symposium for congenital heart disease

Mesoblast Limited today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome was featured at the First Cardiac Regenerative Symposium for Congenital Heart Disease in Baltimore, Maryland on the weekend.

26 Sep 2018

Exercise and diet may reduce obesogenic effects of PFAS

A new study finds that perfluoroalkyl and polyfluoroalkyl substances are associated with increases in weight, but exercise and diet may reduce the obesogenic effects of these environmental contaminants.

26 Sep 2018

New TB vaccine effective in half of the population in phase II trials

GlaxoSmithKline has come up with an experimental vaccine against tuberculosis (TB) that has shown effective prevention of the infection in half of the population it has been administered to. This could be a breakthrough in preventing the killer disease say researchers since most of the recent vaccines developed against the disease have failed to show efficacy.

26 Sep 2018

Common painkiller not effective in controlling chronic pain after traumatic nerve injury

A new study out today in the Journal of Neurology finds that pregabalin is not effective in controlling the chronic pain that sometimes develops following traumatic nerve injury.

25 Sep 2018

Lancaster professor aims to understand how genes affect smoking cessation

The Canadian Institute of Health Research has awarded $929,475 to Professor Jo Knight of Lancaster Medical School, Lancaster Data Science Institute and the Department of Psychiatry at the University of Toronto.

25 Sep 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial for FARXIGA, the broadest SGLT-2 inhibitor CVOT conducted to date.

24 Sep 2018

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD dementia.

24 Sep 2018

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

Ipsen announced today that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, provided a positive opinion for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma in adults who have been previously treated with sorafenib.

21 Sep 2018

NIH launches clinical trial to test infusions of combination antibodies in people with HIV

A clinical trial testing infusions of combination antibodies in people living with HIV has begun at the National Institutes of Health.

20 Sep 2018

AmpliPhi receives positive feedback from FDA for its AB-PA01 product targeting P.aeruginosa infections

AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting.

19 Sep 2018

Novel clinical trial to examine cannabis as potential treatment for essential tremor

Researchers at University of California School of Medicine are preparing to launch a novel clinical trial to examine the safety, efficacy and pharmacological properties of cannabis as a potential treatment for adults with essential tremor.

18 Sep 2018

Resveratrol decreases pain severity and levels of inflammatory biomarkers in osteoarthritis patients

In what researchers state is the first pilot clinical trial to assess the effects of resveratrol on pain severity and levels of inflammatory biomarkers in patients with mild to moderate knee osteoarthritis, the scientists compared treatment with a nonsteroidal anti-inflammatory drug combined with either resveratrol or placebo over 90 days.

18 Sep 2018

ASPREE trial explores whether low dose aspirin can prolong good health in elderly people

The ASPREE trial of more than 19,000 participants in Australia and the US is the largest and most comprehensive study to look at whether the many millions of older people around the world who take (100mg) low dose aspirin to preserve good health are deriving any benefit by doing so.

18 Sep 2018

Placebo News and Research

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Promising vaccine may provide new treatment option for patients with HER2-positive cancers

Early Parkinson’s disease patients wait too long before seeking medical attention

Non-small cell lung cancer patients survive longer when treated with durvalumab

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Novel therapy technique double rate of upper limb recovery in stroke patients

Mesoblast’s MPC therapy for children featured at symposium for congenital heart disease

Exercise and diet may reduce obesogenic effects of PFAS

New TB vaccine effective in half of the population in phase II trials

Common painkiller not effective in controlling chronic pain after traumatic nerve injury

Lancaster professor aims to understand how genes affect smoking cessation

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

NIH launches clinical trial to test infusions of combination antibodies in people with HIV

AmpliPhi receives positive feedback from FDA for its AB-PA01 product targeting P.aeruginosa infections

Novel clinical trial to examine cannabis as potential treatment for essential tremor

Resveratrol decreases pain severity and levels of inflammatory biomarkers in osteoarthritis patients

ASPREE trial explores whether low dose aspirin can prolong good health in elderly people

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News